Relapsing-remitting multiple sclerosis
Not recruitingStudy comparing stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab in patients with aggressive relapsing-remitting multiple sclerosis
Study comparing stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab in patients with aggressive relapsing-remitting multiple sclerosis
- Disease:Relapsing-remitting multiple sclerosis
- Substances:AlemtuzumabCladribine+3
Denmark- Participants:18–64 years
- Substances:Alemtuzumab
- Sponsor:Helse Bergen HF











